On average, each civil conflict will cost a country roughly 30 years of GDP growth. Therefore, a renewed commitment from the international community to address the deteriorating situation in highly fragile states is necessary to both prevent the mass loss of life, but to also prevent the vicious cycle of extreme poverty. Population trends and dynamics (e.g. population growth) can also have a large impact on prospects for poverty reduction. According to the United Nations, "in addition to improving general health and well-being, analysis shows that meeting the reproductive health and contraceptive needs of all women in the developing world more than pays for itself").In 2013, a prevalent finding in a report by the World Bank was that extreme poverty is most prevalent in low-income countries. In these countries, the World Bank found that progress in poverty reduction is the slowest, the poor live under the worst conditions, and the most affected persons are children age 12 and under. International initiatives
Millennium Summit and Millennium Development Goals
In September 2000, world leaders gathered at the Millennium Summit held in New York, launching the United Nations Millennium Project suggested by then UN Secretary-General Kofi Annan. Prior to the launch of the conference, the office of Secretary-General Annan released a report entitled "We The Peoples: The Role of the United Nations in the 21st Century".
Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents. A 2007 meta-analysis suggested when data of trials were combined, mortality was increased in people treated with cefepime compared with other β-lactam antibiotics. In response, the U.S. Food and Drug Administration (FDA) performed their own meta-analysis which found no mortality difference.Cefepime was patented in 1982 by Bristol-Myers Squibb and approved for medical use in 1994. It is available as a generic drug and sold under a variety of trade names worldwide.It was removed from the World Health Organizations List of Essential Medicines in 2019. Medical use
Cefepime is usually reserved to treat moderate to severe nosocomial pneumonia, infections caused by multiple drug-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, and multiple drug-resistant Streptococcus pneumoniae. A particular strength is its activity against Enterobacteriaceae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front-line agent when infection with Enterobacteriaceae is known or suspected. Spectrum of bacterial susceptibility
Cefepime is a broad-spectrum cephalosporin antibiotic and has been used to treat bacteria responsible for causing pneumonia and infections of the skin and urinary tract. Some of these bacteria include Pseudomonas, Escherichia, and Streptococcus species.